Welcome to LookChem.com Sign In|Join Free
  • or
5-Fluorobenzene-1,3-diol, also known as fluororesorcinol, is a benzene derivative and a fluorinated form of resorcinol. It is a chemical compound with potential antitumor and antibacterial properties, making it a versatile building block for the synthesis of various bioactive molecules. Its unique chemical structure and properties have attracted interest in the fields of medicinal chemistry, fluorine chemistry, and organic synthesis.

75996-29-1

Post Buying Request

75996-29-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

75996-29-1 Usage

Uses

Used in Pharmaceutical Industry:
5-Fluorobenzene-1,3-diol is used as a key intermediate in the synthesis of pharmaceuticals for its potential antitumor and antibacterial properties. Its unique chemical structure allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Dye Industry:
5-Fluorobenzene-1,3-diol is used as a building block in the production of dyes due to its chemical properties. Its fluorinated form provides unique characteristics that can enhance the performance and properties of the resulting dyes.
Used in Organic Synthesis:
5-Fluorobenzene-1,3-diol is used as a versatile starting material in organic synthesis for the preparation of various organic compounds. Its chemical structure and properties make it suitable for the synthesis of a wide range of molecules with potential applications in various industries.
Used in Fluorine Chemistry Research:
5-Fluorobenzene-1,3-diol is used as a subject of interest in the field of fluorine chemistry due to its fluorine substituent. Research on 5-FLUOROBENZENE-1,3-DIOL can lead to the development of new synthetic methods and applications involving fluorinated compounds.
Used in Medicinal Chemistry Research:
5-Fluorobenzene-1,3-diol is used as a promising candidate in medicinal chemistry research for its potential antitumor and antibacterial properties. Further studies on 5-FLUOROBENZENE-1,3-DIOL can contribute to the discovery of new drugs and therapeutic agents.

Check Digit Verification of cas no

The CAS Registry Mumber 75996-29-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,9,9 and 6 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 75996-29:
(7*7)+(6*5)+(5*9)+(4*9)+(3*6)+(2*2)+(1*9)=191
191 % 10 = 1
So 75996-29-1 is a valid CAS Registry Number.
InChI:InChI=1/C6H5FO2/c7-4-1-5(8)3-6(9)2-4/h1-3,8-9H

75996-29-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-fluorobenzene-1,3-diol

1.2 Other means of identification

Product number -
Other names 5-Fluororesorcinol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:75996-29-1 SDS

75996-29-1Relevant academic research and scientific papers

Ferroelectric and antiferroelectric "banana phases" of new fluorinated five-ring bent-core mesogens

Nadasi, Hajnalka,Weissflog, Wolfgang,Eremin, Alexey,Pelzl, Gerhard,Diele, Siegmar,Das,Grande, Siegbert

, p. 1316 - 1324 (2002)

Two homologous achiral five-ring mesogens with lateral fluorine substituents on the core and on the outer rings are presented. Both compounds exhibit two B5 phases and the B2 phase. The high-temperature B5 phases possess an antiferroelectric ground state. The low-temperature B5 phase was found to be ferroelectric, which is indicated by the bistable switching. The assignment and characterization of the mesophases is based on XRD measurements, 1H-, 19F-, 13C-NMR and electro-optical measurements.

BTK Inhibitors and uses thereof

-

Paragraph 0510-0515, (2020/05/02)

The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.

FLUORINATED 4' ALKYLUMBELLIFERYL α-D-GLUCOPYRANOSIDES, BIOLOGICAL STERILIZATION INDICATORS INCLUDING THE SAME AND METHODS OF USING THE SAME

-

Page/Page column 58-59, (2020/07/05)

A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a composition, wherein the composition comprises the enzyme substrate, wherein if the frangible container is broken the composition will contact the bacterial spores to form a mixture having an initial pH in the range from 6.0 to 9.0. The enzyme substrate comprises a fluorinated 4'-alkylumbelliferyl α-D-glucopyranoside represented by the structural formula (I) wherein one of R1 and R2 is F and the other is H, and R3 is an alkyl group having from 1 to 12 carbon atoms. A biological sterilization indicator comprising a kit containing isolated components comprising (i) bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of the enzyme substrate and a method of assessing efficacy of a sterilization process are also disclosed.

Compound for treating or preventing hepatopathy (by machine translation)

-

Paragraph 0216-0217; 0218, (2019/10/01)

The invention discloses a compound, an optical isomer or a pharmaceutically acceptable salt, an optical isomer or a pharmaceutically acceptable salt thereof for treating or preventing hepatopathy, and the compound, optical isomer or pharmaceutically acceptable salt thereof can be applied to the preparation of a medicine for treating or preventing liver diseases. (by machine translation)

Preparation method and medicinal application of halogenated benzenediol glucoside

-

Paragraph 0019; 0032-0033, (2019/05/08)

The invention discloses halogenated benzenediol glucoside with the structural formula as shown in the figure (I) in the specification, a preparation method for the compound and novel application of the compound and a pharmaceutical composition containing the compound in the aspect of inhibiting the inflammation of microgliacyte. (Please see the figure (I) in the specification for the structural formula of the halogenated benzenediol glucoside.).

BROMODOMAIN INHIBITORS FOR TREATING DISEASE

-

Paragraph 0237, (2016/03/19)

Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibiting activity of a bromodomain-containing protein in a human or animal subject are also provided.

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING SWEET TASTE

-

Paragraph 0321, (2014/10/04)

The present invention provides edible compositions comprising a sweet taste modulator of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste in a food product.

PROTEIN KINASE INHIBITORS

-

Page/Page column 24; 25, (2014/01/18)

The present invention relates to a novel family of inhibitors o f protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families

PROTEIN KINASE INHIBITORS

-

Paragraph 22; 23; 24, (2014/03/25)

The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families, more particularly Btk, having the general formula (1): A-Y-E-W-Z (1.)

NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF

-

Paragraph 00154, (2013/07/05)

Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP- 1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-l-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin- 1 -yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 75996-29-1